Table 2.
Grade 3 or 4 toxicity of sunitinib in trials with patients treated for renal cell carcinoma and GIST
| RCC | GIST | ||||
|---|---|---|---|---|---|
| Supportive (Motzer, Michaelson, et al 2006) (n = 63) | Pivotal (Motzer, Rini, et al 2006) (n = 106) | Phase III (Motzer, Hutson, et al 2006) (n = 374) | Phase I/II (Maki et al 2005) (n = 97) | Phase III (Demetri et al 2005) (n = 207) | |
| Nonhematological | |||||
| Fatigue | 11% | 8% | 7% | 10% | 7% |
| Diarrhea | 3% | 3% | 5% | 7% | 4% |
| Nausea | 3% | 0% | 3% | 4% | 1% |
| Dermatitis | 2% | 5% | 5% | 7% | 5% |
| Stomatitis | 2% | 5% | 1% | 3% | NA |
| Asymptomatic lipase increase | 21% | 15% | 4% | 13% | NA |
| Hypertension | 2% | 6% | 8% | 17% | 4% |
| Hematological | |||||
| Neutropenia | 13% | 13% | 11% | NA | 8% |
| Anemia | 10% | 6% | 3% | NA | 4% |
| Thrombocytopenia | 0% | 6% | 8% | NA | 5% |
Abbreviations: GIST, gastrointestinal stromal tumor; NA, not available; RCC, renal cell carcinoma.